|Type||Single domain antibody|
|Target||von Willebrand factor (VWF)|
|Other names||ALX-0081, caplacizumab-yhdp|
|Main uses||Thrombotic thrombocytopenic purpura (TTP)|
|Side effects||Nosebleeding, headaches, bleeding gums|
|Chemical and physical data|
|Molar mass||27876.19 g·mol−1|
Caplacizumab, sold under the brand name Cablivi, is a medication used to treat thrombotic thrombocytopenic purpura (TTP). It is used with plasma exchange and immunosuppressive therapy. It is given by injection into a vein or under the skin.
Common side effects include nosebleeding, headaches, and bleeding gums. Use in pregnancy may increase the risk of bleeding in the baby. It is a small antibody that attaches to and inactivates von Willebrand factor.
Caplacizumab was approved for medical use in Europe in 2018 and the United States in 2019. In the United Kingdom a month of treatment costs about £125,000 as of 2021. This amount in the United States costs about 230,000 USD.
It is given at a dose of 10 mg into a vein followed by 10 mg under the skin for at least 30 days.
Mechanism of action
It is a bivalent single-domain antibody (VHH).
- "Caplacizumab-yhdp Monograph for Professionals". Drugs.com. Retrieved 29 December 2021.
- "Cablivi EPAR". European Medicines Agency (EMA). Retrieved 7 September 2020.
- "Cablivi 10 mg powder and solvent for solution for injection - Summary of Product Characteristics (SmPC)". (emc). 22 June 2020. Retrieved 22 August 2020.
- BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1081. ISBN 978-0857114105.
- "Cablivi Prices, Coupons & Patient Assistance Programs". Drugs.com. Retrieved 29 December 2021.
- Immune Drug Tackles Microvascular Thrombosis Disorder. February 2016
- "New Drug Therapy Approvals 2019". U.S. Food and Drug Administration. 31 December 2019. Retrieved 15 September 2020.